Technical Analysis for AVDL - Avadel Pharmaceuticals plc

Grade Last Price % Change Price Change
F 10.76 0.05% 0.01
AVDL closed up 0.28 percent on Wednesday, November 20, 2024, on 74 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down

Date Alert Name Type % Chg
Calm After Storm Range Contraction 0.05%
NR7 Range Contraction 0.05%
NR7-2 Range Contraction 0.05%
Inside Day Range Contraction 0.05%
Wide Bands Range Expansion 0.05%
Oversold Stochastic Weakness 0.05%
Calm After Storm Range Contraction 0.33%
NR7 Range Contraction 0.33%
New 52 Week Low Weakness 0.33%
Wide Bands Range Expansion 0.33%

   Recent Intraday Alerts

Alert Time
Rose Above Previous Day's High 34 minutes ago
Up 2% 34 minutes ago
Up 1% 34 minutes ago
Possible NR7 about 20 hours ago
Possible Inside Day about 20 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Avadel Pharmaceuticals plc Description

Avadel Pharmaceuticals plc operates as a specialty pharmaceutical company in the United States, France, and Ireland. The company primarily develops FT218, which is in a Phase 3 clinical trial for the treatment of narcolepsy patients suffering from excessive daytime sleepiness (EDS) and cataplexy. It also markets three sterile injectable drugs used in the hospital setting, including Akovaz that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia; Bloxiverz, a cholinesterase inhibitor indicated for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery; and Vazculep, a phenylephrine hydrochloride injection indicated for the treatment of clinically important hypotension. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals PLC in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Pharmaceutical Organ Systems Drugs Surgery Psychoactive Drugs Chloride Anesthesia Reversal Amines Sleep Disorders Narcolepsy Choline Phenols Cataplexy Cholinesterase Phenylephrine Muscle Relaxants

Is AVDL a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 19.09
52 Week Low 10.41
Average Volume 1,139,186
200-Day Moving Average 15.17
50-Day Moving Average 13.28
20-Day Moving Average 13.40
10-Day Moving Average 12.78
Average True Range 0.87
RSI (14) 31.51
ADX 30.48
+DI 19.43
-DI 35.36
Chandelier Exit (Long, 3 ATRs) 14.05
Chandelier Exit (Short, 3 ATRs) 13.02
Upper Bollinger Bands 17.12
Lower Bollinger Band 9.67
Percent B (%b) 0.14
BandWidth 55.63
MACD Line -0.70
MACD Signal Line -0.21
MACD Histogram -0.4883
Fundamentals Value
Market Cap 965.41 Million
Num Shares 89.8 Million
EPS -2.15
Price-to-Earnings (P/E) Ratio -5.00
Price-to-Sales 157.87
Price-to-Book 11.76
PEG Ratio 0.07
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 11.41
Resistance 3 (R3) 11.38 11.12 11.30
Resistance 2 (R2) 11.12 10.96 11.14 11.26
Resistance 1 (R1) 10.94 10.85 11.03 10.97 11.23
Pivot Point 10.68 10.68 10.73 10.70 10.68
Support 1 (S1) 10.50 10.52 10.59 10.53 10.27
Support 2 (S2) 10.24 10.41 10.26 10.24
Support 3 (S3) 10.06 10.24 10.20
Support 4 (S4) 10.09